Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases

[1]  D. Roberts,et al.  Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. , 2015, Journal of autoimmunity.

[2]  C. Picard,et al.  B-cell subpopulations in children: National reference values , 2014, Immunity, inflammation and disease.

[3]  B. Banwell,et al.  Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease , 2014, Neurology.

[4]  A. Zelenetz,et al.  Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. , 2013, Clinical lymphoma, myeloma & leukemia.

[5]  T. Ulinski,et al.  Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome? , 2013, Pediatric Nephrology.

[6]  E. Neufeld,et al.  Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. , 2012, Blood.

[7]  R. Voll,et al.  Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides , 2012, PloS one.

[8]  J. Liese,et al.  Reference values for B cell subpopulations from infancy to adulthood , 2010, Clinical and experimental immunology.

[9]  G. Weiner,et al.  Rituximab: mechanism of action. , 2010, Seminars in hematology.

[10]  E. Silverman,et al.  B-Cell Depletion for Autoimmune Thrombocytopenia and Autoimmune Hemolytic Anemia in Pediatric Systemic Lupus Erythematosus , 2009, Pediatrics.

[11]  A. Baruchel,et al.  Prolonged agammaglobulinemia despite unaltered B-cell lymphopoiesis after peritransplant-rituximab administration in a child. , 2008, Transplantation.

[12]  G. Bisogno.  Persistent B-cell depletion after rituximab for thrombocytopenic purpura , 2006, European Journal of Pediatrics.

[13]  P. Lambert,et al.  Reduced Ability of Neonatal and Early-Life Bone Marrow Stromal Cells to Support Plasmablast Survival1 , 2006, The Journal of Immunology.

[14]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[15]  Y. Becker,et al.  Rituximab as Treatment for Refractory Kidney Transplant Rejection , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  E. Lanino,et al.  Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy. , 2003, Journal of hematotherapy & stem cell research.

[17]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[18]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[19]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[20]  Malone Dg.  Mechanism of action of rituximab. , 2001 .

[21]  D. Maloney.  Mechanism of action of rituximab. , 2001, Anti-cancer drugs.

[22]  H. Ochs,et al.  The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. , 1988, The Journal of laboratory and clinical medicine.

[23]  V. Oxelius.  IgG SUBCLASS LEVELS IN INFANCY AND CHILDHOOD , 1979, Acta paediatrica Scandinavica.

[24]  J. Haaijman,et al.  Immunoglobulin class and subclass levels in the serum of CBA mice throughout life. , 1977, Immunology.

[25]  W. O'Fallon,et al.  Serum immunoglobulins. I. Levels in normal children and in uncomplicated childhood allergy. , 1968, Pediatrics.